Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Pageof 9